Program Newsletter
www.HepCChallenge.org
June 2011
Clinical
Trials, Cohort Studies, Pilot Studies
Safety and
efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and
coexisting heart disease.
Durante-Mangoni E, Iossa
D, Pinto D, De Vincentiis L, Ragone
E, Utili R. Dig Liver Dis. 2011 May;43(5):411-5.
http://www.ncbi.nlm.nih.gov/pubmed/21310673
Closure of Ascites Leaks with Fibrin Glue Injection in Patients with
End-Stage Liver Disease.
Sadik K, Laibstain S, Northup
PG, Kashmer D, Bonatti HJ. J
Laparoendosc Adv Surg Tech
A. 2011 May 25. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21612447
Peginterferon with or
without ribavirin has minimal effect on quality of
life, behavioral/ emotional, and cognitive outcomes in children. Rodrigue JR, Balistreri W, Haber B, et al. Hepatology.
2011 May;53(5):1468-75. doi: 10.1002/hep.24248.
http://www.ncbi.nlm.nih.gov/pubmed/21351116
Patient-care practices associated
with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Shimokura G, Chai F, Weber DJ, et al. Infect Control Hosp Epidemiol. 2011 May;32(5):415-24.
http://www.ncbi.nlm.nih.gov/pubmed/21515970
Prevalence of liver disease in veterans with bipolar
disorder or schizophrenia. Fuller BE, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P. Gen Hosp Psychiatry. 2011 May-Jun;33(3):232-7. Epub 2011 May 6.
http://www.ncbi.nlm.nih.gov/pubmed/21601719
Open-label,
ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in
patients with chronic hepatitis C.
Patel
K, Jhaveri R, George J, et al. J Viral Hepat. 2011 May;18(5):331-7. doi:
10.1111/j.1365-2893.2010.01310.x.
http://www.ncbi.nlm.nih.gov/pubmed/20367801
The hepatitis C self-management programme: a randomized controlled trial. Groessl EJ, Weingart KR, Stepnowsky CJ, Gifford AL, Asch SM, Ho SB. J Viral Hepat. 2011 May;18(5):358-68. doi:
10.1111/j.1365-2893.2010.01328.x.
http://www.ncbi.nlm.nih.gov/pubmed/20529203
Clinical
experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Sasadeusz JJ,
Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Addiction. 2011 May;106(5):977-84.
doi:
10.1111/j.1360-0443.2010.03347.x.
http://www.ncbi.nlm.nih.gov/pubmed/21205057
Diagnosis of depression in former injection drug
users with chronic hepatitis C. Scott
JD, Wang CC, Coppel E, Lau A, Veitengruber
J, Roy-Byrne P. J Clin Gastroenterol. 2011 May-Jun;45(5):462-7.
http://www.ncbi.nlm.nih.gov/pubmed/21293293
Psychiatric
and Substance Use Disorders among Methadone Maintenance Patients with Chronic
Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment. Batki SL, Canfield KM, Ploutz-Snyder R. Am J Addict. 2011 Jul;20(4):312-8.
doi:
10.1111/j.1521-0391.2011.00139.x. Epub 2011 May 31.
http://www.ncbi.nlm.nih.gov/pubmed/21679262
Efficacy of
re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic
hepatitis C in Japan.
Oze T, Hiramatsu N, Yakushijin T, et al. J Gastroenterol.
2011 May 3. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21538029
Efficacy of pegylated
interferon-α2a monotherapy in Japanese children with
chronic hepatitis C. Tsunoda T,
Inui A, Etani Y, et al. Hepatol
Res. 2011 May;41(5):399-404. doi: 10.1111/j.1872-034X.2011.00789.x.
http://www.ncbi.nlm.nih.gov/pubmed/21518401
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among
patients with chronic hepatitis C and earlier treatment failure to interferon
and ribavirin: an open-label study in central and
Eastern Europe. Husa P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Urbanek P. Eur J Gastroenterol Hepatol. 2011 May;23(5):375-81.
http://www.ncbi.nlm.nih.gov/pubmed/21502923
Th17 cells are increased with
severity of liver inflammation in patients with chronic hepatitis C. Chang
Q, Wang YK, Zhao Q, Wang CZ, Hu YZ, Wu BY. J Gastroenterol
Hepatol. 2011 May 18. doi: 10.1111/j.1440-1746.2011.06782.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21592230
Basic
and Applied Science, Pre-Clinical Studies
T Helper
Type 1/T Helper Type 17-Related Cytokines in Chronic Hepatitis C Patients
before and after Interferon and Ribavirin Therapy. Fathy A,
Ahmed AS, Metwally L, Hassan A. Med Princ Pract. 2011;20(4):345-9. Epub 2011 May 11.
http://www.ncbi.nlm.nih.gov/pubmed/21576995
Single
nucleotide polymorphism at exon 7 splice acceptor
site of OAS1 gene determines response of hepatitis C virus patients to
interferon therapy. El
Awady MK, Anany MA, Esmat G, et al. J Gastroenterol Hepatol. 2011 May;26(5):843-50. doi: 10.1111/j.1440-1746.2010.06605.x.
http://www.ncbi.nlm.nih.gov/pubmed/21182542
Inhibition of Hepatitis C Virus 3a genotype entry
through Glanthus Nivalis
Agglutinin.
Ashfaq UA, Masoud
MS, Khaliq S, Nawaz Z, Riazuddin S. Virol J. 2011 May 20;8:248.
http://www.ncbi.nlm.nih.gov/pubmed/21599979
Hepatitis
C virus targets the T cell secretory machinery as a
mechanism of immune evasion. Petrovic D, Stamataki
Z, Dempsey E, et al. Hepatology. 2011 Jun;53(6):1846-53. doi:
10.1002/hep.24327. Epub 2011 May 2.
http://www.ncbi.nlm.nih.gov/pubmed/21452285
Expression
profiles of genes associated with viral entry in HCV-infected human liver.
Nakamuta M, Fujino
T, Yada R, et al. J Med Virol.
2011 May;83(5):921-7. doi: 10.1002/jmv.22042.
http://www.ncbi.nlm.nih.gov/pubmed/21412800
Hepatic
Akt expression correlates with advanced fibrosis in
patients with chronic hepatitis C infection. Huang JF, Chuang YH, Dai CY, et al. Hepatol Res. 2011 May;41(5):430-436.
doi:
10.1111/j.1872-034X.2011.00786.x. Epub 2011 Apr 19.
http://www.ncbi.nlm.nih.gov/pubmed/21504518
Hepatitis
C virus core protein induces fibrogenic actions of
hepatic stellate cells via toll-like receptor 2. Coenen M, Nischalke
HD, Krämer B, et al. Lab Invest. 2011 May 2. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21537327
Genetic
determinants in hepatitis C virus-associated mixed cryoglobulinemia:
role of polymorphic variants of BAFF promoter and Fcγ
receptors. Gragnani L, Piluso
A, Giannini C, et al. Arthritis Rheum. 2011 May;63(5):1446-51. doi:
10.1002/art.30274.
http://www.ncbi.nlm.nih.gov/pubmed/21538321
Distinct Functions of NS5A in HCV RNA Replication
Uncovered by Studies with the NS5A Inhibitor BMS-790052.
Fridell RA, Qiu
D, Valera L, Wang C, Rose RE, Gao
M. J Virol. 2011 May 18. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21593143
Estimation of inhibitory quotient using a
comparative equilibrium dialysis assay for prediction of viral response to
hepatitis C virus inhibitors. Mo H, Yang C, Wang K, et al. J
Viral Hepat. 2011 May;18(5):338-48.
doi: 10.1111/j.1365-2893.2010.01314.x.
http://www.ncbi.nlm.nih.gov/pubmed/20456634
Inhibition
of full length Hepatitis C Virus particles of 1a genotype through small
interference RNA.
Ansar M, Ashfaq UA, Shahid I, et al. Virol J. 2011
May 2;8:203.
http://www.ncbi.nlm.nih.gov/pubmed/21535893
HIV/HCV
Coinfection
Hepatitis C
virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in
HIV/HCV-coinfected patients. Medrano
J, Resino S, Vispo E, et
al. J Viral Hepat. 2011 May;18(5):325-30.
doi:
10.1111/j.1365-2893.2010.01309.x.
http://www.ncbi.nlm.nih.gov/pubmed/20456635
Somatic
symptoms and the association between hepatitis C infection and depression in
HIV-infected patients.
Yoon JC, Crane PK, Ciechanowski PS, et al. AIDS
Care. 2011 May 11:1-11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21562994
Low-density lipoprotein receptor
genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C
virus-coinfected patients. Pineda JA, Caruz A, di
Lello FA, et al. AIDS. 2011
May 12. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21572301
Safety and
efficacy of raltegravir in patients with HIV-1 and
hepatitis B and/or C virus coinfection. Rockstroh J, Teppler H, Zhao J, et al. HIV Med. 2011 May 22. doi:
10.1111/j.1468-1293.2011.00933.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/21599819
IL28B gene polymorphisms and
viral kinetics in HIV/hepatitis C virus-coinfected
patients treated with pegylated interferon and ribavirin. Rallón NI,
Soriano V, Naggie S, et al. AIDS. 2011 May 15;25(8):1025-33.
http://www.ncbi.nlm.nih.gov/pubmed/21505315
Impact of IL28B polymorphisms on
response to peginterferon and ribavirin
in HIV–hepatitis C virus-coinfected patients with
prior nonresponse or relapse. Labarga P,
Barreiro P, Mira JA, et al. AIDS. 2011 May 15;25(8):1131-3.
http://www.ncbi.nlm.nih.gov/pubmed/21537116
Treatment of hepatitis C virus
(HCV) infection in patients coinfected with HIV in
the HIV Outpatient Study (HOPS), 1999-2007. Vellozzi C, Buchacz K, Baker R, et al. J Viral Hepat.
2011 May;18(5):316-24. doi: 10.1111/j.1365-2893.2010.01299.x.
http://www.ncbi.nlm.nih.gov/pubmed/20367803
Treatment for hepatitis C virus
with pegylated interferon-{alpha} plus ribavirin induces anti-atherogenic
effects on cardiovascular risk biomarkers in HIV-infected and -uninfected
patients. Masiá M, Robledano C, López N, Escolano C, Gutiérrez F. J Antimicrob Chemother. 2011 May 28. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21622971
Correlation
between FIB4, liver stiffness and metabolic parameters in patients with HIV and
hepatitis C virus co-infection. Bruno R, Sacchi P, Cima S, et al. Dig Liver Dis. 2011 Jul;43(7):575-8.
Epub 2011 May 19.
http://www.ncbi.nlm.nih.gov/pubmed/21596630
Epidemiology,
Diagnostics, and Miscellaneous Works
Irritability:
an underappreciated side effect of interferon treatment for chronic hepatitis
C? Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 May;20(9-10):1215-24.
doi:
10.1111/j.1365-2702.2010.03494.x. Epub 2011 Mar 3.
http://www.ncbi.nlm.nih.gov/pubmed/21371144
Partnering urban academic medical centers and rural
primary care clinicians to provide complex chronic disease care.
Arora S, Kalishman
S, Dion D, et al. Health Aff (Millwood). 2011 Jun;30(6):1176-84. Epub 2011 May 19.
http://www.ncbi.nlm.nih.gov/pubmed/21596757
Immunological/virological
peripheral blood biomarkers and distinct patterns of sleeping quality in
chronic hepatitis C patients. de Almeida CM, de Lima TA, Castro
DB, et al. Scand J Immunol. 2011 May;73(5):486-95. doi:
10.1111/j.1365-3083.2011.02518.x.
http://www.ncbi.nlm.nih.gov/pubmed/21231952
Current
strategies for managing providers infected with bloodborne
pathogens. Turkel S, Henderson DK. Infect Control
Hosp Epidemiol. 2011 May;32(5):428-34.
http://www.ncbi.nlm.nih.gov/pubmed/21515972
Electronic matching of HIV/AIDS and hepatitis C
surveillance registries in three states.
Speers S, Klevens
RM, Vonderwahl C, et al. Public Health Rep. 2011
May-Jun;126(3):344-8.
http://www.ncbi.nlm.nih.gov/pubmed/21553662
Breaking Bad News: The Patient's Viewpoint.
Munoz Sastre MT, Sorum PC, Mullet E. Health
Commun. 2011 May 17:1-7. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21598151
Hepatitis C virus infection among adolescents and
young adults --- Massachusetts, 2002--2009.
Centers
for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly
Rep. 2011 May 6;60(17):537-41.
http://www.ncbi.nlm.nih.gov/pubmed/21544042
Liver
Cancer
Impact
of diabetes mellitus on incidence of hepatocellular
carcinoma in chronic hepatitis C patients treated with interferon-based
antiviral therapy. Hung
CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN. Int J
Cancer. 2011 May 15;128(10):2344-52. doi: 10.1002/ijc.25585.
http://www.ncbi.nlm.nih.gov/pubmed/20669224
Improvement of long-term outcomes in hepatitis C
virus antibody-positive patients with hepatocellular
carcinoma after hepatectomy in the modern era.
Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima
H, Maehara Y. World J Surg. 2011 May;35(5):1072-84.
http://www.ncbi.nlm.nih.gov/pubmed/21468888
Risk
factors for hepatocellular carcinoma in a cohort
infected with hepatitis B or hepatitis C. Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George
J, Dore GJ. J Gastroenterol
Hepatol. 2011 May 26. doi: 10.1111/j.1440-1746.2011.06785.x. [Epub ahead of print]